Cost of breast cancer care in low- and middle-income countries: a scoping review protocol

Erfani, Parsa; Bhangdia, Kayleigh; Mugunga, Jean Claude; Pace, Lydia E.; Fadelu, Temidayo

doi:10.11124/jbies-20-00402

Cited by 8 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A low- and middle-income country have higher rates of breast cancer mortality in comparison to high-income countries and with it comes the higher costs which affects the cancer care delivery, policy and strategies of countries which are crucial components for accessing the good health care ( 13 ). Focusing on the EU-27, breast cancer is the most diagnosed cancer with over 360,000 new female cases (13.3% of all cancer diagnoses), followed by colorectal and prostate, and third overall when considering the most common cause of death ( 21 ).…”

Section: Methodsmentioning

confidence: 99%

“…Many of the medicines used to treat early breast cancer are effective and available at low cost ( 12 ). However, systematic reviews that analyze the cost of breast cancer diagnosis or treatment in low- and middle-income countries are limited, as they consider the cost-effectiveness of specific chemo- and biologic therapies or focus on specific geographic regions ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Medical cost of breast cancer services in Serbia between 2010 and 2019: national data report

Rancic,

Todorovic,

Stepovic

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Medical cost of breast cancer services in Serbia between 2010 and 2019: national data report

Rancic,

Todorovic,

Stepovic

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

“…The scoping review was conducted in accordance with the Joanna Briggs Institute methodology for scoping reviews, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Scoping Review was referenced to ensure that all suggested reporting items were included [23,24]. An a priori protocol was used [25].…”

Section: Methodsmentioning

confidence: 99%

Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background. Understanding the cost of delivering breast cancer (BC) care in low-and middle-income countries (LMICs) is critical to guide effective care delivery strategies. This scoping review summarizes the scope of literature on the costs of BC care in LMICs and characterizes the methodological approaches of these economic evaluations. Materials and Methods. A systematic literature search was performed in five databases and gray literature up to March 2020. Studies were screened to identify original articles that included a cost outcome for BC diagnosis or treatment in an LMIC. Two independent reviewers assessed articles for eligibility. Data related to study characteristics and methodology were extracted. Study quality was assessed using the Drummond et al. checklist.Results. Ninety-one articles across 38 countries were included. The majority (73%) of studies were published between 2013 and 2020. Low-income countries (2%) and countries in Sub-Saharan Africa (9%) were grossly underrepresented. The majority of studies (60%) used a health care system perspective. Time horizon was not reported in 30 studies (33%). Of the 33 studies that estimated the cost of multiple steps in the BC care pathway, the majority (73%) were of high quality, but studies varied in their inclusion of nonmedical direct and indirect costs. Conclusion.There has been substantial growth in the number of BC economic evaluations in LMICs in the past decade, but there remain limited data from low-income countries, especially those in Sub-Saharan Africa. BC economic evaluations should be prioritized in these countries. Use of existing frameworks for economic evaluations may help achieve comparable, transparent costing analyses. The Oncologist 2021;26:1-12 Implications for Practice: There has been substantial growth in the number of breast cancer economic evaluations in lowand middle-income countries (LMICs) in the past decade, but there remain limited data from low-income countries. Breast cancer economic evaluations should be prioritized in low-income countries and in Sub-Saharan Africa. Researchers should strive to use and report a costing perspective and time horizon that captures all costs relevant to the study objective, including those such as direct nonmedical and indirect costs. Use of existing frameworks for economic evaluations in LMICs may help achieve comparable, transparent costing analyses in order to guide breast cancer control strategies.

show abstract

“…Screening can detect the disease early, saving many years of women’s lives and reducing treatment costs for the health system [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Subjective valuation of Iranian women for screening for gene-related diseases: a case of breast cancer

et al. 2023

View full text Add to dashboard Cite

Background About 5–10% of breast cancer cases are attributed to a gene mutation. To perform preventive interventions for women with a gene mutation, genetic screening BRCA tests have recently been implemented in Iran. The present study aimed to determine Iranian women’s subjective valuation for screening BRCA tests for early detection of breast cancer to help policymakers to make decisions about genetic screening tests for breast cancer and to know the applicants. Methods An online survey was completed by women older than 30 years old in Tehran, the capital of Iran in 2021. A hypothetical scenario about genetic screening tests for breast cancer was defined. The subjective valuation for the tests was assessed by a willingness to pay (WTP) using the contingent valuation method (CVM) by payment card. Demographics, history of breast cancers, knowledge, and physiological variables were considered as independent variables, and a logistic regression model assessed the relationship between WTP and the variables. Results 660 women were included. 88% of participants intended to participate in BRCA genetic screening for breast cancer if it were free. The mean WTP for the tests was about $ 20. Based on the logistic regression, income, family history of breast or ovarian cancer, and positive attitude were associated with WTP. Conclusions Iranian women were willing to intend for genetic screening BRCA tests and pay for them as well. The result of the present study is of great importance for policy makers when it comes to funding and determining co-payments for BRCA genetic screening tests. To achieve a high participation rate of women in breast cancer screening plans, a positive attitude should be promoted as a psychological factor. Educational and informative programs can help.

show abstract

Cost of breast cancer care in low- and middle-income countries: a scoping review protocol

Cited by 8 publications

References 26 publications

Medical cost of breast cancer services in Serbia between 2010 and 2019: national data report

Medical cost of breast cancer services in Serbia between 2010 and 2019: national data report

Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review

Subjective valuation of Iranian women for screening for gene-related diseases: a case of breast cancer

Contact Info

Product

Resources

About